List view / Grid view
Lipid nanoparticles have been used to encapsulate CRISPR-Cas9 and deliver it to cells in mice, where it was highly effective at knocking down expression of a target protein.
The researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.
This exclusive interview highlights some of Dr Arthur Suckow’s insights into how his team uses RNA therapies to treat rare diseases such as Charcot-Marie-Tooth 1A.
Japanese researchers showed for the first time processes that are crucial targets for treating liver cancer are enhanced by saturated fatty acid diets.
The research has shown in high-resolution detail how certain lipids interact with pacemaker ion channels to enhance their activity.
In their study, the researchers from the University of Maryland School of Medicine found that the Nsp6 SARS-CoV-2 protein causes heart damage.
The molecules, called SGDGs, may lead to new ways to treat age-related neurological diseases.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
Researchers have developed an mRNA-based cancer vaccine that is delivered directly into the lymphatic system for a more potent response.
A new single-cell nanoparticle targeting-sequencing approach can measure the cellular uptake of lipid nanoparticles carrying mRNA therapies.
A new genetic discovery adds weight to a theory that motor neurone diseases are caused by abnormal lipid processing pathways inside brain cells.
In their latest study, researchers at Moffitt Cancer Center have shown that cancer cells in an acidic environment undergo lipid synthesis and accumulation.
The University at Buffalo has received a $2.3 million grant from the US National Cancer Institute to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.
Researchers have been able to reduce the chronic inflammation associated with multiple sclerosis in a mice model of the disease, by administering one of the resolving lipid mediators of inflammation, Maresin-1.
Researchers have been able to significantly reduce tumours in a pre-clinical model of a rare genetic lung disease.
